Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for Karyopharm Therapeutics (KPTI) over the last 8 years, with Q4 2025 value amounting to $19000.0.

  • Karyopharm Therapeutics' Depreciation and Depletion fell 7654.32% to $19000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $296000.0, marking a year-over-year decrease of 1294.12%. This contributed to the annual value of $296000.0 for FY2025, which is 1294.12% down from last year.
  • As of Q4 2025, Karyopharm Therapeutics' Depreciation and Depletion stood at $19000.0, which was down 7654.32% from $121000.0 recorded in Q3 2025.
  • Karyopharm Therapeutics' Depreciation and Depletion's 5-year high stood at $290000.0 during Q1 2023, with a 5-year trough of $19000.0 in Q4 2025.
  • In the last 5 years, Karyopharm Therapeutics' Depreciation and Depletion had a median value of $102000.0 in 2022 and averaged $128800.0.
  • In the last 5 years, Karyopharm Therapeutics' Depreciation and Depletion soared by 6384.18% in 2023 and then crashed by 7654.32% in 2025.
  • Karyopharm Therapeutics' Depreciation and Depletion (Quarter) stood at $139000.0 in 2021, then decreased by 18.71% to $113000.0 in 2022, then tumbled by 31.86% to $77000.0 in 2023, then rose by 5.19% to $81000.0 in 2024, then plummeted by 76.54% to $19000.0 in 2025.
  • Its Depreciation and Depletion was $19000.0 in Q4 2025, compared to $121000.0 in Q3 2025 and $78000.0 in Q2 2025.